March 2013 Blog Posts (34)

New Diagnostic Test Show High Sensitivity and Specificity in the Early Detection of Pancreatic Cancer

To improve the prognosis of patients with pancreatic cancer, a more accurate serum diagnostic method is required. Now researchers have developed a new diagnostic test that uses a scientific technique known as metabolomic analysis that may be a safe and easy screening method.The researchers believe that this new test may improve the prognosis, offering patients with pancreatic cancer a real survival advantage through earlier detection.

According to data from the…

Continue

Added by Peter Hofland, PhD on March 29, 2013 at 9:30am — No Comments

Study Shows Drop in Cancer Incidence after Closure of Sacramento Reactor may Warrant Full Review of Other Low-level Radiation Risks

A first long-term study of the full-population health impacts of the closure of nuclear reactor in the United States found 4,319 fewer cancers over 20 years, with declines in cancer incidence in 28 of 31 categories (14 of them statistically significant), including notable drops in cancer for women, Hispanics and children.

In their article, published Biomedicine International, an open access peer-reviewed…

Continue

Added by Peter Hofland, PhD on March 28, 2013 at 10:30am — No Comments

Anti-smoking drug Varenicline Reduces Depressive Mood, Craving and Reward Value of Cigarettes - Giving Smokers a Better Chance of Quitting

Results from a behavioral research study designed to learn more about mood and physiological responses in different groups of people attempting to quit smoking published in the March 27 edition of JAMA Psychiatry shows that smokers have a higher probability of quitting smoking and a better overall cessation experience when taking varenicline compared to bupropion and to placebo or unmedicated…

Continue

Added by Peter Hofland, PhD on March 27, 2013 at 4:00pm — No Comments

Study Shows Number of Cancer Survivors Expected to Increase to 18 Million by 2022

According to projections published in the Journal Cancer Epidemiology, Biomarkers & Prevention, the number of people who have survived cancer will rise by 31% from 13.7 million today to nearly 18 million in 2022 (8.8 million males and 9.2 million females). The increased number of cancer survival is the result of the considerable progress that has been made in reducing cancer incidence.  The review shows that among the 3 most…

Continue

Added by Peter Hofland, PhD on March 27, 2013 at 3:00pm — No Comments

New Study on Diet, Lifestyle and Cancer Show Following Basic Recommendations Save Lives

Food is an important factor in determining cancer incidence. Generally, vegetables rich in antioxidants and fibers tend to reduce the development of cancer, while fat-rich food may be associated with increases in breast, colon and prostate cancers. Other factors. such as a sedentary lifestyle and high calorie diet, are also associated with the development of cancer.

A major new study that tracked the diets and disease rates of nearly 380,000 people over 13 years, shows…

Continue

Added by Peter Hofland, PhD on March 27, 2013 at 12:30pm — No Comments

New mRNA-Based Cancer Vaccine for Patients with Castration-Resistant Prostate Cancer Enrolls Patients in a Phase 2b Clinical Trial

A new a double-blind, randomized Phase 2b clinical trial of CV9104 (CureVac GmbH) for the treatment of patients with castration-resistant prostate cancer will enroll up to 200 patients in eight European countries.The purpose of this study is to determine whether the new RNActive-derived prostate cancer vaccine prolongs survival in patients with asymptomatic or minimally symptomatic metastatic prostate cancer that is castrate…

Continue

Added by Peter Hofland, PhD on March 27, 2013 at 7:30am — No Comments

Ganetespib Displayed Greater Antitumor Activity and Prolonged Survival in ALK-positive NSCLC Compared to Crizotinib

Transforming rearrangements of the ALK (anaplastic lymphoma kinase) gene define a unique subset of patients with non–small cell lung carcinoma (NSCLC). While ALK gene rearrangements affect only about 4% of all lung cancers, they are more frequent in adenocarcinomas, in never or light smokers, and seem almost mutually exclusive with activating EGFR or KRAS mutations. Today, the clinical success of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (…

Continue

Added by Peter Hofland, PhD on March 26, 2013 at 2:30pm — No Comments

Frontal Balding in African-American Men Linked to Increased Risk for Developing Prostate Cancer

Data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research shows that baldness is associated with an increased risk of prostate cancer among African-American men. According to published data, publication also showed that risk for advanced prostate cancer increased with younger age and type of baldness.

Prostate cancer is the second leading cause of cancer death in American men, behind only lung…

Continue

Added by Peter Hofland, PhD on March 26, 2013 at 2:30pm — No Comments

March Madness: Colorectal Cancer Prevention and Screening

One of the most important cancer screening procedure for colorectal cancer (CRC) prevention in people over 50 or those with high risk factors is a colonoscopy. The primary goal of a colonoscopy is to prevent deaths from colon cancer. Screening may help identify cancers at an early and potentially treatable stage. Some tests can also prevent the development of cancer by identifying precancerous abnormal growths called adenomatous polyps. In most cases, these polyps can be removed before…

Continue

Added by Peter Hofland, PhD on March 26, 2013 at 10:00am — No Comments

Study Shows Monoclonal Antibody Targets and Kills Leukemia Cells

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody specific for CD44 (RG7356) that targets and directly kills chronic lymphocytic leukemia (CLL) cells. The adhesion molecule CD44 is a transmembrane glycoprotein that is overexpressed in a number of solid tumor and hematologic malignancies and is associated with a poor prognosis. The findings, published in…

Continue

Added by Peter Hofland, PhD on March 25, 2013 at 6:30pm — No Comments

Study Links Higher Soy Consumption in Nonsmoking Chinese Women Before Lung Cancer Diagnosis to Longer Survival

Results from a large observational follow-up study conducted in Shanghai, China, being published online March 25, 2013 in the Journal of Clinical Oncology, reports that nonsmoking Chinese women who consumed more soy before being diagnosed with lung cancer lived longer compared with those who consumed less soy. The study provides the first scientific evidence that soy intake has a favorable effect on lung cancer…

Continue

Added by Peter Hofland, PhD on March 25, 2013 at 3:30pm — No Comments

Scientists at MD Anderson Discover Protein with Key Function in Muscle Involved in Regulating Genes

A key building block of life, actin, is one of the most abundant and highly conserved proteins in eukaryotic cells. First discovered in muscle cells more than 70 years ago, actin has a well-established identity as a cytoplasmic protein that works by linking itself in chains to form filaments. Fibers formed by these actin polymers are crucial to muscle contraction.

When scientists discovered actin in the nucleus, this came as a surprise. Researchers have been working for the…

Continue

Added by Editorial Team on March 24, 2013 at 4:00pm — No Comments

Functional Characteristics of Genetically Engineered Antitumor T Cells Change Over Time After Therapeutic Transfer

Scientists at the at the California Institute of Technology (CalTech) have characterized how the functionality of genetically engineered T cells administered therapeutically to patients with melanoma changed over time. The data, which are published in Cancer Discovery, a journal of the American…

Continue

Added by Peter Hofland, PhD on March 21, 2013 at 6:00pm — No Comments

Functional Characteristics of Genetically Engineered Antitumor T Cells Change Over Time After Therapeutic Transfer

Scientists at the at the California Institute of Technology (CalTech) have characterized how the functionality of genetically engineered T cells administered therapeutically to patients with melanoma changed over time. The data, which are published in Cancer Discovery, a journal of the American…

Continue

Added by Peter Hofland, PhD on March 21, 2013 at 6:00pm — No Comments

Updated Consensus Guidelines Released for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors

Earlier today, the American Society for Colonoscopy and Cervical Pathology (ASCCP) released the Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors.

The updated guidelines are are based on a systematic evidence review and contributions from a group of 47 experts representing 23 professional societies, national…

Continue

Added by Editorial Team on March 21, 2013 at 2:30pm — No Comments

Higher Costs and Greater Risk for Cancer Patients Due to Drug Shortages: Persisting Shortages Despite Efforts to Fix Problems

A national survey of health professionals showed that drug shortages are taking a heavy toll on cancer patients.  The results characterize oncology drug shortages across the United States and the impact of shortages on clinical practice, patient safety, clinical trials, and health care costs.  The researchers conclude that shortages may force treatment changes and delays that, for some patients, may meant worse outcomes, more therapy-related complications and higher costs. investigators…

Continue

Added by Peter Hofland, PhD on March 21, 2013 at 8:30am — No Comments

Engineered Radiopharmaceutical Offers Better Cancer Detection and More Accurate Staging

Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers that have reached the lymph nodes. The diagnostic radiopharmaceutical dye called…

Continue

Added by Peter Hofland, PhD on March 20, 2013 at 8:00pm — No Comments

Results of Phase III Trial with Talimogene Laherparepvec (T-VEC) in Melanoma Shows Statistical Advantage Compared to GM-CSF

Earlier today researchers released top-line results from the Phase III trial in melanoma, evaluating the efficacy and safety of talimogene laherparepvec (Amgen; T-VEC, originally called OncovexGM-CSF, the trial drug was initially under development by BioVex Inc, Oxford, UK, until it was purchased by Amgen in January 2011 and…

Continue

Added by Peter Hofland, PhD on March 19, 2013 at 3:30pm — No Comments

Levels of 13 Genes Elevated in Unaffected Breasts May Help Identify Risk for Hormone-sensitive, Hormone-insensitive Breast Cancer

Researchers at Northwestern University in Chicago confirmed that risk biomarkers that are specific to estrogen receptor (ER) subtypes of breast cancer aid the development and implementation of distinct breast cancer prevention strategies.

According to study results published in Cancer Prevention Research, overexpression…

Continue

Added by Peter Hofland, PhD on March 19, 2013 at 1:30pm — No Comments

Pediatric Research Hospital Receives U.S. Patent for Genetically Modified Human Immune Cells for Cancer Therapy

Improving outcomes of cancer treatment in children greatly depends on the development of new targeted therapies with acceptable short-term and long-term toxicity. Researchers at St. Jude Children's Research Hospital, an internationally recognized pioneering research and treatment center for of children with cancer and other life-threatening diseases, have received a patent from the United States Patent and Trademark Office for the…

Continue

Added by Peter Hofland, PhD on March 19, 2013 at 10:00am — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+